Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab

Patricia F. Groleau, Anna L. Grossberg, Anthony A. Gaspari

Research output: Contribution to journalArticle

Abstract

Pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS) are rare chronic inflammatory dermatoses of unknown etiologies that often are refractory to conventional treatments. The therapeutic benefits of tumor necrosis factor α (TNF-α) inhibitors have been reported in patients with refractory PG or HS. The copresentation of these 2 diseases has previously been described in several cases in the literature and may present a therapeutic challenge. We present the case of a 51-year-old man who developed widespread inflammatory ulcers affecting approximately 50% of the body surface area and subsequent chronic debilitation from severe pain. He was ultimately diagnosed with concurrent PG and HS. Both diseases remitted in response to treatment with infliximab, which resulted in complete restoration of skin integrity and resolution of his chronic severe pain.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalCutis
Volume95
Issue number6
StatePublished - Jan 1 2015
Externally publishedYes

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Hidradenitis suppurativa and concomitant pyoderma gangrenosum treated with infliximab'. Together they form a unique fingerprint.

  • Cite this